Navigation Links
What is the role of focal therapy in low-risk prostate cancer?
Date:5/18/2010

May 2010 -- In the July issue of European Urology, the scientific journal of the European Association of Urology (EAU), S. Eggener et al. discussed in a recent study the significance and impact of focal therapy for low-risk cancer patients.

Since the introduction of prostate cancer screening based on prostate-specific antigen (PSA), over-treatment has increased. A significant proportion of patients diagnosed with prostate cancer have well differentiated, low-volume tumours at minimal risk of impacting their quality of life or longevity. The selection of a treatment strategy, among the multitude of options, has enormous implications for individuals and health care systems.

A conceptually appealing option to patients uncomfortable with observational strategies yet highly concerned about the risks of whole-gland treatment is to bridge elements of active surveillance with whole-gland therapy. This hybrid approach, termed focal therapy, aims to eradicate known cancer foci with the highest likelihood of progressing or metastasizing while attempting to diminish collateral damage to the vital structures essential for maintaining normal urinary and sexual function.

Limitations of focal therapy include the inability to stage or grade the cancer(s) accurately, suboptimal imaging capabilities, uncertainty regarding the natural history of untreated cancer foci, challenges with post-treatment monitoring, and the lack of quality-of-life data compared with alternative treatment strategies.

The aim of the present study was to review the rationale, patient selection criteria, diagnostic imaging, biopsy schemes, and treatment modalities available for the focal therapy of localized prostate cancer.

A National Center for Biotechnology Information PubMed search (www.pubmed.gov) was performed from 1995 to 2009 using medical subject headings ''focal therapy'' or ''ablative'' and ''prostate cancer'.' Additional articles were extracted based on recommendations from an expert panel of authors.

One of the conclusions of the study is that focal therapy for prostate cancer is a promising and emerging treatment strategy for men with a low risk of cancer progression or metastasis. Evaluation in formal prospective clinical trials is essential before this new strategy is accepted in clinical practice.


'/>"/>

Contact: Lindy Brouwer
l.brouwer@uroweb.org
European Association of Urology
Source:Eurekalert

Related medicine news :

1. UV LED therapy shows promising results in preventing focal seizures
2. Well-tolerated radiotherapy provides longer life to patients with recurrent brain cancer
3. Combination therapy targets stubborn leukemia stem cells
4. Study demonstrates art therapys effectiveness in pediatric asthma
5. Physical Therapy Online Continuing Education Courses Undergo an Inevitable Evolution
6. Complimentary Injury Screenings Available at All AthletiCo Physical and Occupational Therapy Centers
7. Phase II study of an oral therapy for Gaucher disease yields positive results
8. Magnet Therapy May Ease Hard-to-Treat Depression
9. FDA Reviews Side Effects From Prostate Cancer Therapy
10. Finding cancer cold spots can help minimize radiotherapy side-effects
11. Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures Act’s Impact on ... Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          ... in order to thrive this year? , The passage of the act means devicemakers ...
(Date:1/19/2017)... ... January 19, 2017 , ... Infinity® Massage Chairs announced today that Dan Grover ... and marketing strategies. Grover comes with a total of 15 years experience in consumer ... as Executive Vice President of Direct Sales at Traeger® Wood Pellet Grills. , ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... age-related lines and wrinkles. Few people know that popular cosmetic fillers ... Richard Buckley, who is medical director of the MilfordMD Cosmetic Dermatology Surgery & ...
(Date:1/18/2017)... Charlottesville, Virginia (PRWEB) , ... January 18, 2017 , ... ... New studies are released almost daily linking gut health to chronic disease, mental health ... the New Year ” as an important resolution to consider. , For one Charlottesville ...
(Date:1/18/2017)... ARBOR, Mich. USA; SAN JOSE, Calif, USA; and SHANGHAI, China ... ... (PRWEB) January 18, 2017 -- Global public health ... to reduce arsenic V (pentavalent arsenic) to NSF/ANSI 53: Drinking ... for drinking water treatment units. This certification verifies that MicroCeramics’ ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
(Date:1/18/2017)... Oregon and PUNE, India , January 18, 2017 ... Research, titled, "Polyphenol Market by Product Type and by Application: Global Opportunity Analysis ... $757 million in 2015, and is expected to reach $1,127 million by 2022, ... the market in 2015, with two-fifths share, in terms of revenue. ... ...
(Date:1/18/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The global CINV drugs market to grow at a ... Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. To ...
Breaking Medicine Technology: